MX2023005180A - Compuestos de union a il-2r\03b2?c y usos de estos. - Google Patents

Compuestos de union a il-2r\03b2?c y usos de estos.

Info

Publication number
MX2023005180A
MX2023005180A MX2023005180A MX2023005180A MX2023005180A MX 2023005180 A MX2023005180 A MX 2023005180A MX 2023005180 A MX2023005180 A MX 2023005180A MX 2023005180 A MX2023005180 A MX 2023005180A MX 2023005180 A MX2023005180 A MX 2023005180A
Authority
MX
Mexico
Prior art keywords
2rî2î3c
binding compounds
binding
compounds
agonists
Prior art date
Application number
MX2023005180A
Other languages
English (en)
Inventor
William J Dower
Michael C Needels
Ronald W Barrett
Alice V Bakker
Steven E Cwirla
Original Assignee
Medikine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/089,515 external-priority patent/US11718654B2/en
Application filed by Medikine Inc filed Critical Medikine Inc
Publication of MX2023005180A publication Critical patent/MX2023005180A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulgan compuestos de unión a IL-2Rß?c, y composiciones farmacéuticas que comprenden los compuestos de unión a IL-2Rß?c. Los compuestos de unión a IL-2Rß?c pueden actuar como agonistas de IL-2R y son útiles para tratar el cáncer, una enfermedad autoinmunitaria y una enfermedad inflamatoria.
MX2023005180A 2020-11-04 2021-11-04 Compuestos de union a il-2r\03b2?c y usos de estos. MX2023005180A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/089,515 US11718654B2 (en) 2019-11-05 2020-11-04 IL-2R-βγ binding compounds
PCT/US2021/058085 WO2022098890A2 (en) 2020-11-04 2021-11-04 IL-2Rβγc BINDING COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2023005180A true MX2023005180A (es) 2023-05-15

Family

ID=89666483

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005180A MX2023005180A (es) 2020-11-04 2021-11-04 Compuestos de union a il-2r\03b2?c y usos de estos.

Country Status (9)

Country Link
EP (2) EP4268901A3 (es)
JP (1) JP2023548861A (es)
KR (1) KR20230097168A (es)
CN (1) CN116964072A (es)
AU (1) AU2021376351A1 (es)
CA (1) CA3197344A1 (es)
IL (1) IL302575A (es)
MX (1) MX2023005180A (es)
WO (1) WO2022098890A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11746139B2 (en) 2020-02-03 2023-09-05 Medikine, Inc. IL-7Rαγc binding compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525033A (ja) * 2004-12-22 2008-07-17 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド Ｂ群連鎖球菌
BR122021012517A2 (pt) * 2018-08-06 2021-08-10 Medikine, Inc. Ligante il-2rgamac, composto compreendendo referido ligante, composição farmacêutica e uso do referido ligante
BR112022008744A2 (pt) * 2019-11-05 2022-07-19 Medikine Inc Ligante de il-2rss, ligante de il-2r¿c, composto de ligação a il-2r¿¿c, composição farmacêutica, método para tratar uma doença em um paciente, método para expandir células imunes, método de uma terapia celular, método para reforçar uma vacina, método para modificar a resposta imune e ácido nucleico

Also Published As

Publication number Publication date
AU2021376351A1 (en) 2023-06-08
KR20230097168A (ko) 2023-06-30
JP2023548861A (ja) 2023-11-21
CN116964072A (zh) 2023-10-27
EP4268901A3 (en) 2024-01-17
WO2022098890A2 (en) 2022-05-12
WO2022098890A3 (en) 2022-07-14
EP4268901A2 (en) 2023-11-01
CA3197344A1 (en) 2022-05-12
IL302575A (en) 2023-07-01
EP4240394A2 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
MX2022005411A (es) COMPUESTOS DE UNIÓN A IL-2RßYC.
MX2022009390A (es) Compuestos de unión a il-7r¿¿c.
MX2022005404A (es) Compuestos de fijación a il-2r e il-7r dual.
PH12020500241A1 (en) Cytokine conjugates for the treatment of autoimmune diseases
PH12020551923A1 (en) Methods and compositions for treating cancer
MX2022011818A (es) Metodos y composiciones para el direccionamiento de canceres de celulas t.
WO2007061874A3 (en) Methods and compositions for use in treating cancer
NZ767596A (en) Antibodies that bind cd39 and uses thereof
WO2004034990A3 (en) Methods and compositions for use in treating cancer
MX2020012091A (es) Composiciones anti-cd24 y usos de las mismas.
JOP20200016B1 (ar) أجسام مضادة لـ cd137
MX2021005350A (es) Compuestos de piridazinona y usos de los mismos.
CL2008001943A1 (es) Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes.
MY184628A (en) Afucosylated anti-fgfr2iiib antibodies
MX2022012621A (es) Enlazadores de variantes de carga.
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
PH12020500664A1 (en) C3-binding agents and methods of use thereof
JOP20210314A1 (ar) Tigit وجزيئات ربط pd-1/tigit
WO2017214170A3 (en) Baff-r antibodies and uses thereof
WO2020131586A3 (en) Methods for identifying neoantigens
WO2021038296A3 (en) Modified tff2 polypeptides
MX2022016544A (es) Agentes de union a lair-1 y metodos para su uso.
MX2023005180A (es) Compuestos de union a il-2r\03b2?c y usos de estos.
BR112022009405A2 (pt) Composições e métodos para imunoterapia
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof